Page 34

M. Mendonça, et al.: Dor na Osteoartrose: Modelos Animais e Testes Farmacológicos
9. Arnoldi CC, Arnoldi CC, Djurhuus JC, Heerfordt J, Karle A. Intraosseous 38. Ferreira-Gomes J, Adães S, Mendonça M, Castro-Lopes JM. Analgesic
phlebography, intraosseous pressure measurements and 99mTC-poly- effects of lidocaine, morphine and diclofenac on movement-induced
phosphate scintigraphy in patients with various painful conditions in the nociception, as assessed by the Knee-Bend and CatWalk tests in a rat
hip and knee. Ata Orthop Scand. 1980;51:19-28. model of osteoarthritis. Pharmacol Biochem Behav. 2012;101:617-24.
10. Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M. Synovial 39. Bjordal JM, Ljunggren AE, Klovning A, Slordal L. Non-steroidal anti-in-
membrane inflammation and cytokine production in patients with early flammatory drugs, including cyclo-oxygenase2 inhibitors, in osteoar-
osteoarthritis. J Rheumatol. 199724:365-71. thritic knee pain: meta-analysis of randomised placebo controlled trials.
11. Hunter DJ, McDougall JJ, Keefe FJ. The symptoms of osteoarthritis and BMJ. 2004;329:1317.
the genesis of pain. Rheum Dis Clin North Am. 2008;34(3): 623-43. 40. Matthews GL, Hunter DJ. Emerging drugs for osteoarthritis. Expert Opin
12. Chandran P, Pai M, Blomme EA, Hsieh GC, Decker MW, Honore P. Emerg Drugs. 2011;16:479-91.
Pharmacological modulation of movement-evoked pain in a rat model 41. Bennett DL. Neurotrophic factors: important regulators of nociceptive
of osteoarthritis. Eur J Pharmacol. 2009;613(1-3):39-45. function. Neuroscientist. 2001;7(1):13-7.
13. Bove SE, Calcaterra SL, Brooker RM, et al. Weight bearing as a measure 42. Sah DW, Ossipo MH, Porreca F. Neurotrophic factors as novel therapeu-
of disease progression and efficacy of anti-inflammatory compounds in tics for neuropathic pain. Nat Rev Drug Discov. 2003;2(6): 460-72.
a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthri- 43. Indo Y, Tsuruta M, Hayashida Y, et al. Mutations in the TRKA/NGF rece-
tis Cartilage. 2003;11(11):821-30. tor gene in patients with congenital insensitivity to pain with anhidrosis.
14. Kidd BL. Osteoarthritis and joint pain. Pain. 2006;123(1-2):6-9. Nat Genet. 1996;13(4):485-8.
15. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the 44. Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ. p38 MAPK activation by
management of hip and knee osteoarthritis: part III: Changes in evi- NGF in primary sensory neurons after inflammation increases TRPV1 levels
dence following systematic cumulative update of research published and maintains heat hyperalgesia. Neuron. 2002 Sep 26;36(1):57-68.
through January 2009. Osteoarthritis Cartilage. 2010 Apr;18(4):476-99. 45. Heumann R, Korsching S, Bandtlow C, Thoenen H. Changes of nerve
16. Bosomworth NJ. Exercise and knee osteoarthritis: benefit or hazard? growth fator synthesis in nonneuronal cells in response to sciatic nerve
Can Fam Physician. 2009;55(9):871-8. transection. J Cell Biol. 1987;104(6):1623-31.
17. Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. 46. Vanelderen P, Rouwette T, Kozicz T, et al. The role of brain-derived
Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006 neurotrophic fator in different animal models of neuropathic pain. Eur J
Jan 25(1). Pain. 2010;14(5):473-9.
18. Howes F, Buchbinder R, Winzenberg TB. Opioids for osteoarthritis? 47. Saadé NE, Massaad CA, Ochoa-Chaar CI, Jabbur SJ, Safieh-Garabe-
Weighing benefits and risks: a Cochrane Musculoskeletal Group review. dian B, Atweh SF. Upregulation of proinflammatory cytokines and nerve
J Fam Pract. 2011 Apr;60(4):206-12. growth fator by intraplantar injection of capsaicin in rats. J Physiol.
19. Nüesch E, Rutjes AW, Husni E, Welch V, Jüni P. Oral or transdermal 2002;15;545(1):241-53.
opioids for osteoarthritis of the knee or hip. Cochrane Database Syst 48. Lewin GR, Rueff A, Mendell LM. Peripheral and central mechanisms of
Rev. 2009;7(4). NGF-induced hyperalgesia. Eur J Neurosci. 1994;6(12):1903-12.
20. Cepeda MS, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis. 49. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of
Cochrane Database Syst Rev. 2006;19(3). pain from osteoarthritis of the knee. N Engl J Med.2010; 363(16):1521-31.
21. Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy 50. Zorbas M, Hurst S, Shelton D, Evans M, Finco D, Butt M. A multiple-dose
for treating osteoarthritis. Cochrane Database Syst Rev. 2005 Apr;18(2). toxicity study of tanezumab in cynomolgus monkeys. Regul Toxicol
22. Reichenbach S, Sterchi R, Scherer M, et al. Meta-analysis: chondroitin Pharmacol. 2011;59(2):334-42.
for osteoarthritis of the knee or hip. Ann Intern Med. 2007 Apr;17; 51. Yang KG, Raijmakers NJ, van Arkel ER, et al. Autologous interleukin-1
146(8):580-90. recetor antagonist improves function and symptoms in osteoarthritis
23. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Visco- when compared to placebo in a prospective randomized controlled
supplementation for the treatment of osteoarthritis of the knee. Cochrane trial. Osteoarthritis Cartilage. 2008;16(4):498-505.
Database Syst Rev. 2006;19(2). 52. Fox BA, Stephens MM. Treatment of knee osteoarthritis with Orthokine-
24. Nüesch E, Rutjes AW, Trelle S, Reichenbach S, Jüni P. Doxycycline for derived autologous conditioned serum. Expert Rev Clin Immunol.
osteoarthritis of the knee or hip. Cochrane Database Syst Rev. 2009;7(4). 2010;6(3):335-45.
25. Reichenbach S, Rutjes AW, Nüesch E, Trelle S, Jüni P. Joint lavage for 53. Malemud CJ. Anticytokine therapy for osteoarthritis: evidence to date.
osteoarthritis of the knee. Cochrane Database Syst Rev. 2010;12(5). Drugs Aging.2010;27(2):95-115.
26. Choong PF, Dowsey MM. Update in surgery for osteoarthritis of the 54. Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of
knee. Int J Rheum Dis. 2011 May;14(2):167-74. anakinra in osteoarthritis of the knee: a multicenter, randomized, double-
27. Ameye LG, Young MF. Animal models of osteoarthritis: lessons learned blind, placebo-controlled study. Arthritis Rheum. 2009;61(3): 344-52 .
while seeking the “Holy Grail”. Curr Opin Rheumatol. 2006;18(5):537-47. 55. Felson DT. The sources of pain in knee osteoarthritis. Curr Opin Rheu-
28. Blaney Davidson EN, Scharstuhl A, Vitters EL, et al. Reduced transform- matol. 2005;17(5):624-8.
ing growth fator-beta signaling in cartilage of old mice: role in impaired 56. Bajaj P, Bajaj P, Graven-Nielsen T, Arendt-Nielsen L. Osteoarthritis and
repair capacity. Arthritis Res Ther. 2005;7:R1338–47. its association with muscle hyperalgesia: an experimental controlled
29. Johnson K, Svensson CI, Etten DV, et al. Mediation of spontaneous knee study. Pain. 2001;93(2):107-14.
osteoarthritis by progressive chondrocyte ATP depletion in Hartley 57. Wylde V, Palmer S, Learmonth ID, Dieppe P. Test-retest reliability of
guinea pigs. Arthritis Rheum. 2004;50:1216–25. Quantitative Sensory Testing in knee osteoarthritis and healthy partici-
30. Guingamp C, Gegout-Pottie P, Philippe L, Terlain B, Netter P, Gillet P. pants. Osteoarthritis Cartilage.2011;19(6):655-8.
Mono-iodoacetate-induced experimental osteoarthritis: a dose-response 58. Hochman JR, Gagliese L, Davis AM, Hawker GA. Neuropathic pain
study of loss of mobility, morphology, and biochemistry. Arthritis Rheum. symptoms in a community knee OA cohort. Osteoarthritis Cartilage.
1997;40(9):1670-9. 2011;19(6):647-54.
31. Kikuchi T, Sakuta T, Yamaguchi T. Intra-articular injection of collagenase 59. Chappell AS, Ossanna MJ, Liu-Seifert H, et al. Duloxetine, a centrally
induces experimental osteoarthritis in mature rabbits. Osteoarthritis and acting analgesic, in the treatment of patients with osteoarthritis knee
Cartilage. 1998;6(3):177-86. pain: a 13-week, randomized, placebo-controlled trial. Pain. 2009;146:
32. Ferreira-Gomes J, Adães S, Castro-Lopes JM. Assessment of move- 253-60.
ment-evoked pain in osteoarthritis by the knee-bend and CatWalk tests: 60. Beyreuther B, Callizot N, Stöhr T. Antinociceptive efficacy of lacosamide
a clinically relevant study. J Pain. 2008;9(10):945-54. in the monosodium iodoacetate rat model for osteoarthritis pain. Arthri-
33. Appleton CT, Pitelka V, Henry J, Beier F. Global analyses of gene ex- tis Res Ther. 2007;9(1):14.
pression in early experimental osteoarthritis. Arthritis Rheum. 2007; 61. Vonsy JL, Ghandehari J, Dickenson AH. Differential analgesic effects of
56(6):1854-68. morphine and gabapentin on behavioural measures of pain and dis-
34. Barve RA, Minnerly JC, Weiss DJ, et al. Transcriptional profiling and ability in a model of osteoarthritis pain in rats. Eur J Pain. 2009;
pathway analysis of monosodium iodoacetate-induced experimental 13(8):786-93.
osteoarthritis in rats: relevance to human disease. Osteoarthritis Carti- 62. Combe R, Bramwell S, Field MJ. The monosodium iodoacetate model
lage. 2007;15(10):1190-8. of osteoarthritis: a model of chronic nociceptive pain in rats? Neurosci
35. Fernihough J, Gentry C, Malcangio M, et al. Pain related behaviour in Lett. 2004;370(2-3):236-40.
two models of osteoarthritis in the rat knee. Pain. 2004;112(1-2):83-93. 63. Ivanavicius SP, Ball AD, Heapy CG, Westwood FR, Murray F, Read SJ.
36. Pomonis JD, Boulet JM, Gottshall SL, et al. Development and pharma- Structural pathology in a rodent model of osteoarthritis is associated
cological characterization of a rat model of osteoarthritis pain. Pain. with neuropathic pain: increased expression of ATF-3 and pharmaco-
2005;114(3):339-46. logical characterisation. Pain. 2007;128(3):272-82.
37. Haufman KR, Hughes C, Morrey BF, Morrey M, An KN. Gait character- 64. Liu P, Okun A, Ren J, et al. Ongoing pain in the MIA model of osteoar-
istics of patients with knee osteoarthritis. J Biomech. 2001;34(7): 907-15. thritis. Neurosci Lett. 2011;493(3):72-5. DOR
33